{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T06:04:02Z","timestamp":1789365842878,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure is the end-stage of various cardiovascular diseases. Although a variety of drugs have slowed down the progression of the disease, the prognosis of heart failure patients remains unsatisfactory. Vericiguat can improve left ventricular function, but there is relatively less research on its effect on right ventricular function. This study aimed to evaluate whether vericiguat can improve the right ventricular function of heart failure patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with left ventricular ejection fraction\u2009&amp;lt;\u200945% who were hospitalized for the first time in the Department of Cardiology, The Second Affiliated Hospital of Soochow University from January 1, 2023, to December 31, 2024 were included and divided into two groups. The baseline and 3-month follow-up clinical characteristics, laboratory data, routine transthoracic echocardiogram parameters, and medication use of patients were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 90 eligible patients were finally included, with 60 cases in the vericiguat group and 30 cases in the control group. In the vericiguat group, right ventricular function improved significantly after treatment. The tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE\/PASP) ratio increased significantly [0.51\u2009\u00b1\u20090.22 vs. 0.60\u2009\u00b1\u20090.22,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001]. Right atrial longitudinal dimension index significantly decreased [30.07\u2009\u00b1\u20095.80\u2005mm\/m\n                      <jats:sup>2<\/jats:sup>\n                      vs. 28.57\u2009\u00b1\u20095.43\u2005mm\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001], as did the Right atrial transverse dimension index [23.21\u2009\u00b1\u20095.13\u2005mm\/m\n                      <jats:sup>2<\/jats:sup>\n                      vs. 21.86\u2009\u00b1\u20094.40\u2005mm\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012] and right ventricular basal diameter index [22.48\u2009\u00b1\u20093.96\u2005mm\/m\n                      <jats:sup>2<\/jats:sup>\n                      vs. 21.07\u2009\u00b1\u20093.59\u2005mm\/m\n                      <jats:sup>2<\/jats:sup>\n                      ,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001]. Pulmonary arterial systolic pressure decreased significantly [41.47\u2009\u00b1\u200916.25\u2005mmHg vs. 36.20\u2009\u00b1\u200914.32\u2005mmHg,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006]. In the control group, no significant changes were observed in right heart function parameters. Multiple linear regression analysis showed that the increase in \u0394TAPSE\/PASP was not significantly associated with changes in left ventricular function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vericiguat treatment was associated with a reduction in pulmonary artery systolic pressure, improves right ventricle-pulmonary artery coupling, and promotes structural reverse remodeling of the right atrium and right ventricle in heart failure patients. These right heart benefits occur independently of changes in left ventricular structure and function. Vericiguat showed good short-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1894753","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:38:40Z","timestamp":1789364320000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term right heart reverse remodeling with vericiguat in HFrEF: reductions in pulmonary arterial pressure and chamber dimensions"],"prefix":"10.3389","volume":"13","author":[{"given":"Yaoting","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Second Affiliated Hospital of Soochow University","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3760\/cma.j.issn.0253-3758.2019.11.004","article-title":"Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China","volume":"47","author":"Wang","year":"2019","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.puhe.2024.02.015","article-title":"Burden of heart failure in Asia, 1990\u20132019: findings from the global burden of disease study 2019","volume":"230","author":"Zhang","year":"2024","journal-title":"Public Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.3390\/jcm11175199","article-title":"Prevalence, characteristics, management and outcomes of patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"11","author":"Escobar","year":"2022","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/ejhf.3550","article-title":"The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries\u2014a global congestive heart failure (G-CHF) study","volume":"27","author":"Leong","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: jacc review topic of the week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1080\/14656566.2021.1937121","article-title":"Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options","volume":"22","author":"Hulot","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1476976","DOI":"10.3389\/fcvm.2024.1476976","article-title":"Vericiguat combined with \u201cnew quadruple\u201d therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study","volume":"11","author":"Zhao","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3760\/cma.j.issn.0253-3758.2018.10.004","article-title":"Chinese Guidelines for the diagnosis and treatment of heart failure 2018","volume":"46","year":"2018","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1002\/ehf2.15032","article-title":"Clinical profile, associated events and safety of vericiguat in a real-world cohort: the verita study","volume":"11","author":"Galv\u00e1n Ruiz","year":"2024","journal-title":"Esc Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","first-page":"132524","DOI":"10.1016\/j.ijcard.2024.132524","article-title":"Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: insights from a 6-month real-world study","volume":"417","author":"Tian","year":"2024","journal-title":"Int J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1253\/circrep.CR-24-0076","article-title":"Effect of vericiguat on left ventricular reverse remodeling in patients who have heart failure with reduced ejection fraction\u2014special focus on patients without quadruple medical therapy","volume":"6","author":"Fujii","year":"2024","journal-title":"Circ Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"132441","DOI":"10.1016\/j.ijcard.2024.132441","article-title":"Effectiveness of vericiguat on right ventricle to pulmonary artery uncoupling associated with heart failure with reduced ejection fraction","volume":"415","author":"Hashimoto","year":"2024","journal-title":"Int J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40261-022-01166-2","article-title":"Pharmacological anti-remodelling effects of disease-modifying drugs in heart failure with reduced ejection fraction","volume":"42","author":"Correale","year":"2022","journal-title":"Clin Drug Investig"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/cts.13677","article-title":"Vericiguat, a novel sgc stimulator: mechanism of action, clinical, and translational science","volume":"16","author":"Trujillo","year":"2023","journal-title":"Clin Transl Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10741-024-10425-7","article-title":"Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?","volume":"29","author":"Correale","year":"2024","journal-title":"Heart Fail Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/01.CIR.102.14.1718","article-title":"Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management","volume":"102","author":"Moraes","year":"2000","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1002\/ehf2.14515","article-title":"Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left-sided heart diseases","volume":"10","author":"Satoh","year":"2023","journal-title":"Esc Heart Fail"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ehf2.14802","article-title":"Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction","volume":"11","author":"Suzuki","year":"2024","journal-title":"ESC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1894753\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:38:42Z","timestamp":1789364322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1894753\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":20,"alternative-id":["10.3389\/fcvm.2026.1894753"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1894753","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1894753"}}